Palatin Technologies, Inc. (OTCMKTS:PTNT – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $13.77 and traded as high as $24.77. Palatin Technologies shares last traded at $24.77, with a volume of 46 shares traded.
Palatin Technologies Price Performance
The firm has a market capitalization of $966,800.00, a price-to-earnings ratio of -15.59 and a beta of -1.59. The firm has a 50 day moving average price of $26.34 and a 200-day moving average price of $13.91.
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Featured Articles
- Five stocks we like better than Palatin Technologies
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
